Sparfloxacin therapy for experimental endocarditis caused by methicillin-resistant staphylococcus aureus

Chemotherapy

Volumn 42, Issue 2, 1996, Pages 133-139

  Maserati, Renato ^a   Cagni, A E ^a   Segu C ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

Experimental endocarditis; Rabbit; Sparfloxacin; Staphylococcus aureus

Indexed keywords

POLYPEPTIDE ANTIBIOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN; VANCOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL COUNT; BACTERIAL ENDOCARDITIS; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; INTRAVENOUS DRUG ADMINISTRATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; RABBIT; STAPHYLOCOCCUS INFECTION;

EID: 0030027090     PISSN: 00093157     EISSN: 14219794     Source Type: Journal    
DOI: 10.1159/000239432     Document Type: Article

References (29)

1. Garau J, Grassi C, Hosie J, Huchon G, Legakis N, Lode H, Segev S, Wij-nands WJ: Treatment of community-acquired pneumonia (CAP): A comparison of sparfloxacin (S), amoxicillin clavulanic acid (AC) and erythromycin (E) (abstract 1,025). 33rd Intersci Conf Antimicrob Agents Chemother, 1993.
2. Henry' NK, Rouse MS, Whitesell AL, McConnell BA, Wilson WR: Treatment of methicillin-resistant Staphylococcus aureus experimental osteomyelitis with ciprofloxacin or vancomycin alone or in combination with rifampin. Am J Med 1987 (suppl 4A):82.
3. Canton E, Peman J, Jimenez MT, Ramon MS, Gobernado M: In vitro activity of sparfloxacin compared with those of five other quinolones. Antimicrob Agents Chcmother 1992;36:558-565.
4. Cooper MA, Andrews JM, Ashby JP, Mattews RS, Wise R: In vitro activity of sparfloxacin, a new quin-olone antimicrobial agent. J Antimicrob Chemother 1990;26:667-676.
5. Nakamura S, Kurobe N, Ohue T, Hashimoto M, Shimizu M: Pharmacokinetics of a novel quinolone, AT-4140, in animals. Antimicrob Agents Chemother 1990,34:89-93.
6. Chaudry AZ, Knapp CC, Sierra-Madero J, Washington JA: Anti-staphylococcal activities of sparfloxacin (CI-978; AT-4140), ofloxacin and ciprofloxacin. Antimicrob Agents Chemother 1990:34:1843-1845.
7. Perlman B, Freedman LR: Experimental endocarditis. II: A new method for the production of staphylococcal endocarditis of the aortic valve in rabbits. Yale J Biol Med 1971;44:206-224.
8. Sullam PM, Tauber MG, Hackbart CJ, Chambers HF, Scott KG, Sandc MA: Pefloxacin therapy for experimental endocarditis caused by mcthicillin-susceptible or mcthicil-lin-resistant strains of Staphylococcus aureus. Antimicrob Agents Che-mother 1985;27:685-687.
9. Trexler-Hessen M, Pitsakis PG, Kaye D: Oral temafloxacin versus vancomycin for therapy of experimental endocarditis caused by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Che-mother 1990:34:1143-1145.
10. Boscia JE, Kobasa WD, Kaye D: Enoxacin compared with cefopera-zone for the treatment of experimental Enterobacter aerogenes endocarditis. Antimicrob Agents Che-mother 1985;27:708-711.
11. Strunk RW, Gratz JC, Maserati R, Scheid WM: Comparison of ciprofloxacin with azlocillin plus tobramycin in the therapy of experimental Pseudomonas aeruginosa endocarditis. Antimicrob Agents Che-mother 1985;28:428-432.
12. Gehanno P: Treatment of acute purulent sinusitis (APS) in adults: A comparison of two Sparfloxacin (S) regimens and cefuroxime-axetil (CA) (abstract 1,025). 33rd Intersci Conf Antimicrob Agents Chemo-ther, 1993.
13. Aubier M, Geslin P, Regamcy C, Verster R, European Study Group: Treatment of suspected pneumococcal community-acquired pneumonia (CAP): Comparison of Sparfloxacin (S) and amoxicillin (A) (abstract 1024). 33rd Intersci Conf Antimicrob Agents Chemother, 1993.
14. Yura J: Clinical studies on Sparfloxacin in the surgery (abstract 252). 4th Int Symp on New Quinolones, 1992.
15. Lewin CS, Morrissey I, Smith JT: The bactericidal activity of Sparfloxacin. J Antimicrob Chemother 1992;30:625-632.
16. Baddour LM, Christensen GD, Lowrance JH, Simpson A: Pathogenesis of experimental endocarditis. Rev Infect Dis 1989;3:452-463.
17. Nakamura S, Nakamura M, Bogaki M, Kojima T, Yoshida H: Mechanism of action of Sparfloxacin (abstract 1239). 30th Intersci Conf Antimicrob Agents Chemother, 1990.
18. Fillastre JP, Montay G, Etienne I, Dhib M, Vivicr N, Bruno R, Gay G, Schott D: Pharmacokinetics of Sparfloxacin in patients with renal impairment (abstract 749). 32nd Intersci Conf Antimicrob Agents Chemother, 1992.
19. Wolfson JS, Hooper DC: The fluor-quinoloncs: Clinical and laboratory considerations. Clin Microbiol Newslett 1992; 14:11-17.
20. Montay G, Bruno R, Thebauld JJ, Vergniol JC, Chassard D, Ebmeier M, Gaillot J: Dose-dependent phar-makokinetic study of sparfloxacin (SPFX) in healthy young volunteers (abstract 1248). 30th Intersci Conf Antimicrob Agents Chemother, 1990.
21. Fekety R: Vancomycin and teico-planin; in Mandell GL, Douglas RG, Bennett JE (eds): Principles and Practice of Infectious Diseases. Edinburgh, Churchill Livingstone, 1990, pp 317-323.
22. Blatter M, Entenza J, Moreillon P, Glauser MP: Parenteral sparfloxacin (SPFX) compared to vancomycin (V) in the treatment (RX) of experimental endocarditis (EE) due to mcthicillin-rcsistant S. aureus (abstract 150). 33rd Intersci Conf Antimicrob Agents Chemother, 1993.
23. Kaatz GW, Sco SM. Kenneth CL, Bailey EM, Rybak MJ: CI-960, a new fluorquinolone, for therapy of experimental ciprofloxacin-susceptible and -resistant Staphylococcus aureus endocarditis. Antimicrob Agents Chemother 1992;36:1192-1197.
24. Piddock LJV: New quinolones and gram-positive bacteria. Antimicrob Agents Chemother 1994;38:163-169.
25. Hackbarth CJ, Chambers HF, Sande MA: Serum bactericidal activity of rifampin in combination with other antimicrobial agents against Staphylococcus aureus. Antimicrob Agents Chemother 1986; 29:611-613.
26. Van der Auwera P, Joly P: Comparative in-vitro activities of teicoplan-in, vancomycin, coumermycin and ciprofloxacin, alone and in combination with rifampicin or LM427, against Staphylococcus aureus. J Antimicrob Chemother 1987; 19:313-320.
27. Drancourt M, Stein A, Argenson JN, Zannier A, Curvale G, Raoult D: Oral rifampin plus ofloxacin for treatment of Staphylococcus- infected orthopedic implants. Antimicrob Agents Chemother 1993;37: 1214-1218.
28. Dworkin RJ, Sande MA, Leeand BL, Chambers HF: Treatment of right-sided S. aureus endocarditis in intravenous drug users with ciprofloxacin and rifampin. Lancet 1989; ii: 1071-1073.
29. Kaatz GW, Seo SM, Barriere SL, Albrecht LM, Rybak MJ: Ciprofloxacin and rifampin, alone and in combination, for therapy of experimental Staphylococcus aureus endocarditis. Antimicrob Agents Chemother 1989;33:1184-1187.